

Response to May 16, 2006 Office Action
 Serial No. 10/722,702
 CVT No. 01-157-CIP


AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listing of claims in the application. For the Examiner's convenience, a complete listing of all pending claims is attached as Appendix A.

LISTING OF CLAIMS:

RECEIVED
 CENTRAL FAX CENTER
 SEP 14 2006

1. (presently amended) A compound of the formula:



Formula I

wherein:

R¹ is optionally substituted lower alkyl of 1-6 carbon atoms, optionally substituted cycloalkyl of 3-6 carbon atoms, optionally substituted aryl or phenyl optionally substituted by halo, optionally substituted heteroaryl;

X is a covalent bond or optionally substituted alkylene of 1-3 carbon atoms;

R² is R⁴-Z-Y-C≡C- in which Y is alkylene of 1-3 carbon atoms, Z is oxygen, sulfur or -NH-, and R⁴ is phenyl optionally substituted by halo or lower alkoxy; or

R² is optionally substituted pyrazolyl optionally substituted by phenyl or benzyl, which are optionally substituted by halo, lower alkyl, or lower alkoxy; or

R² is pyrazolyl substituted by (lower alkyl)-O-C(O)-, -C(O)NH₂, -C(O)NH-(lower alkyl), cycloalkyl of 3-6 carbon atoms, pyrimidinyl, pyridinyl, benzoxazolyl, quinazolyl, isoquinazolyl, or pyrazolyl, said pyrimidinyl, pyridinyl, benzoxazolyl, quinazolyl, isoquinazolyl, or pyrazolyl all of which are optionally substituted by 1, 2 or 3 lower alkyl groups;

Response to May 16, 2006 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP

~~in which Y is optionally substituted alkylene of 1-3 carbon atoms, Z is oxygen, sulfur or NH, and R⁴ is optionally substituted aryl phenyl optionally substituted by halo or lower alkoxy or optionally substituted heteroaryl; and~~
R³ is hydroxymethyl or -C(O)-NR⁵R⁶;
in which R⁵ and R⁶ are independently hydrogen or lower alkyl.

2. (presently amended) The compound of claim 1, wherein R² is optionally substituted pyrazol-1-yl substituted by phenyl, which is optionally substituted by halo, lower alkyl, or lower alkoxy.

3. (presently amended) The compound of claim 2, wherein R¹ is optionally substituted lower alkyl of 1-6 carbon atoms or optionally substituted aryl phenyl optionally substituted by halo, and R³ is hydroxymethyl.

4. (canceled)

5. (canceled)

6. (original) The compound of claim 3, wherein R¹ is ~~optionally substituted~~ lower alkyl of 1-6 carbon atoms and X is a covalent bond.

7. (original) The compound of claim 6, wherein R¹ is methyl and R² is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(methylamino)purin-9-yl}oxolane-3,4-diol.

8. (original) The compound of claim 6, wherein R¹ is n-propyl and R² is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(n-propylamino)purin-9-yl}oxolane-3,4-diol.

Response to May 16, 2006 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP

9. (original) The compound of claim 6, wherein R^1 is methyl and R^2 is 4-(4-chlorobenzylaminocarbonyl)pyrazol-1-yl, namely (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)purin-2-yl}pyrazol-4-yl)-N-(4-chlorophenyl)carboxamide.

10. (original) The compound of claim 6, wherein R^1 is methyl and R^2 is 4-(4-chlorobenzylaminocarbonyl)pyrazol-1-yl, namely (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)purin-2-yl}pyrazol-4-yl)-N-(4-chlorophenyl)carboxamide.

11. (presently amended) The compound of claim 4 1, wherein R^1 is lower alkyl of 1-6 carbon atoms, R^2 is pyrazo-1-yl substituted by ~~optionally substituted heteroaryl~~ (lower alkyl)-O-C(O)-, -C(O)NH₂, -C(O)NH-(lower alkyl), cycloalkyl of 3-6 carbon atoms, pyrimidinyl, pyridinyl, benzoxazolyl, quinazolyl, isoquinazolyl, or pyrazolyl, said pyrimidinyl, pyridinyl, benzoxazolyl, quinazolyl, isoquinazolyl, or pyrazolyl all of which are optionally substituted by 1, 2 or 3 lower alkyl groups, R^3 is hydroxymethyl, and X is a covalent bond.

12. (original) The compound of claim 11, wherein R^1 is n-propyl and R^2 is 4-(pyrid-2-yl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[4-(pyridin-2-yl)pyrazolyl]-6-(n-propylamino)purin-9-yl} oxolane-3,4-diol.

13. (presently amended) The compound of claim 5, wherein R^1 is ~~optionally substituted aryl~~ phenyl optionally substituted by halo and X is ~~alkylene~~ methylene.


14. (presently amended) The compound of claim 13, wherein R^1 is ~~3-iodobenzyl~~ 3-iodophenyl and R^2 is 4-(4-methoxyphenyl)pyrazol-1-yl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[4-(4-methoxyphenyl)pyrazolyl]-6-(3-iodobenzylamino)purin-9-yl} oxolane-3,4-diol.

Response to May 16, 2006 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP

15. (presently amended) The compound of claim 1, wherein R^2 is ~~optionally substituted~~ pyrazol-4-yl optionally substituted by benzyl.
16. (presently amended) The compound of claim 15, wherein R^1 is ~~optionally substituted alkyl~~ lower alkyl of 1-6 carbon atoms and R^3 is hydroxymethyl or optionally substituted aryl, R^3 is hydroxymethyl, and X is a covalent bond.
17. (original) The compound of claim 16, wherein R^1 is methyl, R^2 is 1-benzylpyrazol-4-yl, R^3 is hydroxymethyl, and X is a covalent bond, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[1-benzylpyrazolyl]-6-(methylamino)purin-9-yl}oxolane-3,4-diol.
18. (original) The compound of claim 16, wherein R^1 is n-propyl, R^2 is 1-benzylpyrazol-4-yl, R^3 is hydroxymethyl, and X is a covalent bond, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-{2-[1-benzylpyrazolyl]-6-(n-propylamino)purin-9-yl}oxolane-3,4-diol.
19. (original) The compound of claim 1, wherein R^2 is R^4 -Z-Y-C≡C-.
20. (presently amended) The compound of claim 19, wherein R^4 is ~~optionally substituted~~ phenyl optionally substituted by halo or lower alkoxy, R^3 is hydroxymethyl, and Y is alkylene of 1-3 carbon atoms.
21. (original) The compound of claim 20, wherein R^4 is phenyl optionally substituted by methoxy or chloro, and Y is methylene.
22. (presently amended) The compound of claim 21, wherein R^1 is ~~optionally substituted~~ alkyl of 1-6 carbon atoms, X is a covalent bond, ~~and R^3 is hydroxymethyl~~.

Response to May 16, 2006 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP


23. (original) The compound of claim 22, wherein R^1 is methyl, R^4 is phenyl and Z is oxygen, namely 2-hydroxymethyl-5-[6-methylamino-2-(3-phenoxypropyn-1-yl)purin-9-yl]-tetrahydrofuran-3,4-diol.
24. (canceled) A method of treating a disease state in a mammal that is alleviable by treatment with a A_3 adenosine receptor agonist, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of claim 1.
25. canceled) The method of claim 24, wherein the disease state is cancer.
26. (canceled) The method of claim 24, wherein the disease state is neutropenia.
27. (original) A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.
28. (canceled) A process for the preparation of a compound of Formula I:




in which R^2 is optionally substituted pyrazol-1-yl;
comprising:

Response to May 16, 2006 Office Action
 Serial No. 10/722,702
 CVT No. 01-157-CIP

contacting a compound of the formula:




with a compound of formula:



29. (canceled) The process of claim 28, wherein the reaction is conducted in an inert solvent chosen from methanol, ethanol, n-propanol, isopropanol, and t-butanol.

30. (canceled) A process for the preparation of a compound of Formula I:




in which R² is optionally substituted pyrazol-4-yl;


comprising

contacting a compound of the formula:

Response to May 16, 2006 Office Action
 Serial No. 10/722,702
 CVT No. 01-157-CIP



with a compound of the formula:



in the presence of a palladium complex and a copper salt in an inert solvent, and contacting the product with a mild acid.


31. (canceled) The process of claim 30, wherein the palladium complex is Pd(PPh₃)₄, the copper salt is CuI, the inert solvent is N,N-dimethylformamide, and the mild acid is ammonium fluoride.

32. (canceled) A process for the preparation of a compound of claim 1, in which R² is R⁴-Z-Y-C≡C-;

comprising:


contacting in an inert solvent a compound of the formula:

Response to May 16, 2006 Office Action
Serial No. 10/722,702
CVT No. 01-157-CIP



(12)

with a compound of the formula:



(13)

in the presence of a mild base, a copper salt and a palladium catalyst.

33. (canceled) The process of claim 32, wherein the inert solvent is N, N-dimethylformamide, the base is triethylamine, the copper salt is copper iodide, and the palladium catalyst is dichlorobis-(triphenylphosphine)palladium(II).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.